RUNX1/AML1 mutant collaborates with BMI1 overexpression in the development of human and murine myelodysplastic syndromes

Blood

Volumn 121, Issue 17, 2013, Pages 3434-3446

  Harada, Yuka ^a   Inoue, Daichi ^b   Ding, Ye ^a   Imagawa, Jun ^a   Doki, Noriko ^b   Matsui, Hirotaka ^a   Yahata, Takashi ^c   Matsushita, Hiromichi ^c   Ando, Kiyoshi ^c   Sashida, Goro ^d   Iwama, Atsushi ^d   Kitamura, Toshio ^b   Harada, Hironori ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b THE UNIVERSITY OF TOKYO   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BMI1 PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; MUTANT PROTEIN; TRANSCRIPTION FACTOR RUNX1; BMI1 PROTEIN, HUMAN; CD34 ANTIGEN; MESSENGER RNA; RUNX1 PROTEIN, HUMAN;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL MUTANT; CELL PROLIFERATION; CELL SELF-RENEWAL; CONTROLLED STUDY; DYSPLASIA; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MALE; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SELF CONCEPT; ANIMAL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL TRANSFORMATION; FLOW CYTOMETRY; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AGED; ANIMALS; ANTIGENS, CD34; BLOTTING, WESTERN; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FLOW CYTOMETRY; HUMANS; MALE; MICE; MICE, INBRED C57BL; MUTATION; MYELODYSPLASTIC SYNDROMES; PHENOTYPE; POLYCOMB REPRESSIVE COMPLEX 1; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

MLCS; MLOWN;

EID: 84879350954     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-434423     Document Type: Article

References (50)

1. Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999; 23(2):166-175.
2. Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene. 2004;23(24):4284-4296.
3. Liew E, Owen C. Familial myelodysplastic syndromes: a review of the literature. Haematologica. 2011;96(10):1536-1542.
4. Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood. 2004; 103(6):2316-2324.
5. Preudhomme C, Warot-Loze D, Roumier C, et al. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood. 2000;96(8):2862-2869.
6. Dicker F, Haferlach C, Kern W, Haferlach T, Schnittger S. Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood. 2007;110(4):1308-1316.
7. Silva FPG, Swagemakers SMA, Erpelinck-Verschueren C, et al. Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status. Blood. 2009;114(14):3001-3007.
8. Tang JL, Hou HA, Chen CY, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood. 2009;114(26):5352-5361.
9. Schnittger S, Dicker F, Kern W, et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood. 2011;117(8):2348-2357.
10. Kuo MC, Liang DC, Huang CF, et al. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia. 2009;23(8):1426-1431.
11. Ernst T, Chase A, Zoi K, et al. Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. Haematologica. 2010;95(9):1473-1480.
12. Harada H, Harada Y, Tanaka H, Kimura A, Inaba T. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood. 2003;101(2):673-680.
13. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood. 2004;104(5):1474-1481.
14. Zharlyganova D, Harada H, Harada Y, et al. High frequency of AML1/RUNX1 point mutations in radiation-associated myelodysplastic syndrome around Semipalatinsk nuclear test site. J Radiat Res (Tokyo). 2008;49(5):549-555.
15. Imagawa J, Harada Y, Shimomura T, et al. Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia. Blood. 2010;116(26): 6018-6022.
16. Ding Y, Harada Y, Imagawa J, Kimura A, Harada H. AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. Blood. 2009; 114(25):5201-5205.
17. Beer PA, Delhommeau F, LeCouédic JP, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010;115(14):2891-2900.
18. Zhao LJ, Wang YY, Li G, et al. Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia. Blood. 2012; 119(12):2873-2882.
19. Grossmann V, Kohlmann A, Zenger M, et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia. 2011; 25(3):557-560.
20. Tahirov TH, Inoue-Bungo T, Morii H, et al. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta. Cell. 2001;104(5):755-767.
21. Bravo J, Li Z, Speck NA, Warren AJ. The leukemia-associated AML1 (RUNX1)—CBF beta complex functions as a DNA-induced molecular clamp. Nat Struct Biol. 2001;8(4):371-378.
22. Watanabe-Okochi N, Kitaura J, Ono R, et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood. 2008;111(8): 4297-4308.
23. Cattoglio C, Facchini G, Sartori D, et al. Hot spots of retroviral integration in human CD341 hematopoietic cells. Blood. 2007;110(6): 1770-1778.
24. Schwieger M, Löhler J, Fischer M, Herwig U, Tenen DG, Stocking C. A dominant-negative mutant of C/EBPalpha, associated with acute myeloid leukemias, inhibits differentiation of myeloid and erythroid progenitors of man but not mouse. Blood. 2004;103(7):2744-2752.
25. Xu F, Li X, Wu L, et al. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring. Ann Hematol. 2011;90(6):643-653.
26. Mihara K, Chowdhury M, Nakaju N, et al. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood. 2006;107(1):305-308.
27. Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, Nimer SD. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood. 2002; 99(1):15-23.
28. Tonks A, Pearn L, Tonks AJ, et al. The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood. 2003; 101(2):624-632.
29. Mulloy JC, Cammenga J, Berguido FJ, et al. Maintaining the self-renewal and differentiation potential of human CD341 hematopoietic cells using a single genetic element. Blood. 2003; 102(13):4369-4376.
30. D’Costa J, Chaudhuri S, Civin CI, Friedman AD. CBFbeta-SMMHC slows proliferation of primary murine and human myeloid progenitors. Leukemia. 2005;19(6):921-929.
31. Wunderlich M, Krejci O, Wei J, Mulloy JC. Human CD341 cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability. Blood. 2006;108(5): 1690-1697.
32. Shen SW, Dolnikov A, Passioura T, et al. Mutant N-ras preferentially drives human CD341 hematopoietic progenitor cells into myeloid differentiation and proliferation both in vitro and in the NOD/SCID mouse. Exp Hematol. 2004;32(9):852-860.
33. Chou FS, Wunderlich M, Griesinger A, Mulloy JC. N-Ras(G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene. Blood. 2011;117(7):2237-2240.
34. Chung KY, Morrone G, Schuringa JJ, Wong B, Dorn DC, Moore MA. Enforced expression of an FLT3 internal tandem duplication in human CD341 cells confers properties of self-renewal and enhanced erythropoiesis. Blood. 2005;105(1):77-84.
35. Rizo A, Dontje B, Vellenga E, de Haan G, Schuringa JJ. Long-term maintenance of human hematopoietic stem/progenitor cells by expression of BMI1. Blood. 2008;111(5):2621-2630.
36. Kato N, Kitaura J, Doki N, et al. Two types of C/ EBPa mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models. Blood. 2011;117(1):221-233.
37. Ito M, Hiramatsu H, Kobayashi K, et al. NOD/ SCID/g(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100(9):3175-3182.
38. Tsuzuki S, Hong D, Gupta R, Matsuo K, Seto M, Enver T. Isoform-specific potentiation of stem and progenitor cell engraftment by AML1/RUNX1. PLoS Med. 2007;4(5):e172.
39. Motoda L, Osato M, Yamashita N, et al. RUNX1 protects hematopoietic stem/progenitor cells from oncogenic insult. Stem Cells. 2007;25(12):2976-2986.
40. Niimi H, Harada H, Harada Y, et al. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Leukemia. 2006;20(4):635-644.
41. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011; 364(26):2496-2506.
42. van der Lugt NM, Domen J, Linders K, et al. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev. 1994;8(7):757-769.
43. Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 2003; 423(6937):302-305.
44. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 2003;423(6937):255-260.
45. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999;397(6715):164-168.
46. Iwama A, Oguro H, Negishi M, et al. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity. 2004;21(6):843-851.
47. Rizo A, Horton SJ, Olthof S, et al. BMI1 collaborates with BCR-ABL in leukemic transformation of human CD341 cells. Blood. 2010;116(22):4621-4630.
48. Yu M, Mazor T, Huang H, et al. Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors. Mol Cell. 2012; 45(3):330-343.
49. Rizo A, Olthof S, Han L, Vellenga E, de Haan G, Schuringa JJ. Repression of BMI1 in normal and leukemic human CD34(1) cells impairs self-renewal and induces apoptosis. Blood. 2009; 114(8):1498-1505.
50. Liu J, Cao L, Chen J, et al. BMI1 regulates mitochondrial function and the DNA damage response pathway. Nature. 2009;459(7245): 387-392.